260 related articles for article (PubMed ID: 3872168)
1. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
2. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
3. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
Shu SY; Chou T; Sakai K
J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
[TBL] [Abstract][Full Text] [Related]
6. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.
Chang AE; Shu SY; Chou T; Lafreniere R; Rosenberg SA
Cancer Res; 1986 Jul; 46(7):3426-30. PubMed ID: 2939946
[TBL] [Abstract][Full Text] [Related]
7. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
8. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
Chou T; Chang AE; Shu SY
J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
[TBL] [Abstract][Full Text] [Related]
9. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.
Awwad M; North RJ
Cancer Res; 1990 Apr; 50(8):2228-33. PubMed ID: 2317810
[TBL] [Abstract][Full Text] [Related]
11. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
12. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Shu S; Chou T; Rosenberg SA
J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
14. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
15. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
16. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
17. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
18. Immunity to a 3-methylcholanthrene-induced fibrosarcoma in the C57BL/6 mouse: in vivo analysis by the adoptive tumor neutralization test.
Poupon MF; Lespinats G; Kolb JP; Payelle B
J Natl Cancer Inst; 1979 Apr; 62(4):989-94. PubMed ID: 311871
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
20. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
Sakai K; Chang AE; Shu S
Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
